Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1353032 | 0.90 | MEN1 (0.56) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL5533137 | 0.90 | MEN1 (0.57) | MEN1KMT2AALDH1A1POLBMAPT | |
| SCHEMBL29269275 | 0.86 | ALDH1A1 (0.57) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL11683221 | 0.85 | BRAF (0.53) | MEN1KMT2AALDH1A1POLBMAPT | |
| SCHEMBL4858061 | 0.85 | KMT2A (0.67) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL1662861 | 0.84 | NPC1 (0.58) | MEN1KMT2AALDH1A1POLBMAPT | |
| SCHEMBL19893787 | 0.82 | KMT2A (0.58) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL3606953 | 0.81 | SMN1; SMN2 (0.60) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4958960 | 0.81 | ALDH1A1 (0.77) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL1663288 | 0.81 | KCNMA1 (0.60) | MEN1KMT2AALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | MEN1 3294/4885KMT2A 3851/4885ALDH1A1 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.